Lipidoses

Lipidoses are a group of rare diseases that affect how your body handles fats (lipids). This happens because of problems with the enzymes that break down fats inside your cells. These conditions can cause various symptoms depending on the specific type of lipidosis.

Condition

What people with Lipidoses report

Every report comes from a Lived member, sent anonymously.

Have you tried Enzyme Replacement Therapy for Lipidoses?

NameHow it went

About Lipidoses

What It Is

Lipidoses, also called lipid storage diseases, are a group of rare inherited disorders in which fatty substances (lipids) build up inside the body's cells. Normally, enzymes inside small compartments of each cell called lysosomes break these fats down so the body can reuse them. In a lipidosis, one of those enzymes is missing or does not work properly, so a particular fat accumulates and, over time, damages the tissue where it collects. Lipidoses is an umbrella term, not a single disease. It includes Gaucher disease, Niemann-Pick disease, Fabry disease, Tay-Sachs and Sandhoff disease, Krabbe disease, metachromatic leukodystrophy, Farber disease and acid lipase deficiency, among others. Which fat builds up, and where, shapes how each one shows itself. Some mainly affect the brain and nerves, causing loss of skills, seizures or problems with movement and swallowing. Others mainly enlarge the liver and spleen, weaken bones or lower blood counts, and Fabry disease affects nerves, kidneys, heart and blood vessels. Severity varies enormously. Some forms begin in infancy and progress quickly, while others start in adolescence or adulthood and move slowly. These conditions are different from high cholesterol, which is a common problem with fats in the blood rather than an inherited enzyme defect inside cells.

Causes & Risk Factors

Lipidoses are caused by changes in a gene that carries the instructions for one lipid-processing enzyme. They are inherited, not caused by diet, lifestyle or anything a person or parent did. Most types are autosomal recessive. A child is affected only when both parents pass on a changed copy of the gene. Parents who each carry one copy are usually healthy, and with each pregnancy there is a 25% chance the child will have the disorder, a 50% chance the child will be a healthy carrier and a 25% chance the child inherits neither copy. Fabry disease is the exception. Its gene is on the X chromosome, so it mainly affects males, while females who carry it often have milder or more variable symptoms and occasionally severe ones. A mother who carries the gene has a 50% chance of passing it to each child, and an affected father passes it to all his daughters but none of his sons. Some types are more common in particular communities, such as Gaucher, Tay-Sachs and Niemann-Pick type A among people of Ashkenazi Jewish ancestry. Carriers of the Gaucher gene, as well as people with the disease, also have a higher risk of Parkinson's disease.

How It's Diagnosed

Because these disorders are rare and early signs overlap with many common conditions, diagnosis can take time. A clinician usually starts with the pattern of symptoms, such as developmental slowing or loss of skills in a child, an enlarged liver or spleen, unexplained low blood counts, or, in Fabry disease, burning pain in the hands and feet. The key tests look for the specific defect. An enzyme assay measures how active a particular enzyme is in a blood sample, and low activity points to a specific disorder. Genetic testing then identifies the gene change, which confirms the type, can guide treatment choice and allows relatives to be tested. In some types, urine tests show the stored material, and occasionally a tissue sample (biopsy) is needed. An eye exam can find a cherry-red spot at the back of the eye in several infant forms. Some US states include certain lipidoses, most notably Krabbe disease, in newborn screening. Families with a known history can have carrier testing before or during pregnancy, and a genetic counselor can explain the results and options.

Treatment Options

Treatment depends on the exact type and subtype, so confirming the specific diagnosis comes first. There is no cure for most lipidoses, but for some types treatment can substantially reduce the buildup and protect organs, and for all types supportive care can ease symptoms and maintain comfort and function. Enzyme replacement therapy supplies the missing enzyme through regular intravenous infusions. It works well for the body symptoms of Gaucher disease type 1 and type 3, such as enlarged organs, low blood counts and bone problems, and is also used in Fabry disease, where it can reduce fat storage, ease pain and help preserve organ function in some people. Olipudase alfa (Xenpozyme) treats the non-brain effects of acid sphingomyelinase deficiency (Niemann-Pick types A and B). Because these enzymes do not cross into the brain, they do not treat brain involvement. Other approaches act differently. Substrate reduction therapy, such as the oral medicine eliglustat for Gaucher type 1, lowers how much of the fat the body makes. Migalastat (Galafold), an oral medicine, helps a faulty enzyme work in adults with Fabry disease who have a specific gene change it can act on. For Niemann-Pick type C, two oral medicines approved in 2024, arimoclomol (Miplyffa, used together with miglustat) and levacetylleucine (Aqneursa), treat the neurological effects. For some brain-affecting types, timing is critical. A stem cell transplant can lengthen life and improve outcomes in early-onset Krabbe disease, and a one-time gene therapy, atidarsagene autotemcel (Lenmeldy), is approved for certain children with metachromatic leukodystrophy before symptoms appear or very early in the juvenile form. Both work best before significant damage has occurred. For many types, including Tay-Sachs, Sandhoff and other gangliosidoses, only supportive care is available. That can include seizure medicines, nutrition and feeding support, physical therapy and treatment of complications. In Fabry disease, blood pressure medicines and other kidney and heart care matter alongside specific therapy, and some people eventually need dialysis or a kidney transplant.

What to Expect

The outlook ranges widely. Infant-onset forms such as classic Tay-Sachs, Niemann-Pick type A and infantile Krabbe disease usually progress quickly, and many affected children do not survive early childhood. Later-onset forms tend to progress more slowly, and many people with forms that begin later, or that have effective treatment such as Gaucher type 1, live into adulthood with ongoing medical care. For people on enzyme replacement, life includes regular infusions. Care is usually coordinated by a metabolic or genetics specialist with other specialists according to the organs involved, such as neurology, kidney, heart or liver care, and periodic blood tests, imaging and organ checks track whether treatment is working. When the nervous system is affected, families often need help with mobility, communication, feeding and seizures as needs change. Early involvement of therapists, palliative care and family support services can make daily life more manageable, and patient organizations and clinical research networks can connect families with specialists and trials.

When to Seek Help

Ask for an evaluation if a child loses skills they had already learned, falls behind in development, or has an unexplained enlarged belly, liver or spleen, or if an adult has unexplained low platelets, bone pain with an enlarged spleen, or burning pain in the hands and feet with reduced sweating. If a lipidosis runs in your family, talk with a genetic counselor before or early in pregnancy. For someone already diagnosed, contact the care team promptly about new seizures, a noticeable loss of abilities, or new trouble swallowing or feeding, since these can signal progression and may change the care plan.

Questions to Ask Your Doctor

  1. 1.Which specific lipidosis is this, and how was the type confirmed?
  2. 2.Is there a treatment that targets this type, and what can it realistically do for the body and the brain?
  3. 3.What changes should we watch for over the next year, and how will progress be monitored?
  4. 4.Should other family members have carrier or genetic testing, and can you refer us to a genetic counselor?
  5. 5.Are there specialist centers or clinical trials we should consider?

Last reviewed • Oct 2026

Educational content, not medical advice.